Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioid epidemic

Clinicians’ Use of ‘Safer’ Opioid-Prescribing Practices Spotty

Anne Harding  |  March 5, 2019

NEW YORK (Reuters Health)—Many U.S. clinicians aren’t following risk-mitigation practices for opioid prescribing, new findings show. “In response to this national opioid crisis, consensus-based safer opioid prescribing guidelines have been published and state laws regulating opioid prescribing practices have been enacted,” Daniel P. Alford, MD, of Boston University School of Medicine, and colleagues write in…

Filed under:AnalgesicsDrug Updates Tagged with:opioidOpioid abuseopioid crisisprescribing

Former Insys CEO Pleads Guilty to Opioid Kickback Scheme

Nate Raymond  |  January 10, 2019

BOSTON (Reuters)—The former chief executive of Insys Therapeutics Inc pleaded guilty on Wednesday to participating in a nationwide scheme to bribe doctors to prescribe an addictive opioid medication and has agreed to become a government witness. Michael Babich, who resigned as the Arizona-based drugmaker’s CEO in 2015, pleaded guilty in federal court in Boston to…

Filed under:Uncategorized Tagged with:guilty pleaInsys CEOInsys Therapeutics IncMichael Babichopioid crisisopioid kickback scheme

Insys to Pay $150 Million to Settle U.S. Opioid Kickback Probe

Nate Raymond  |  August 8, 2018

(Reuters)—Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication. The tentative deal announced by the Arizona-based drugmaker marked a major step in Insys’ efforts to resolve an…

Filed under:Uncategorized Tagged with:FentanylInsys settlementInsys Therapeutics IncJohn KapoorMichael BabichSubsys opioid drugU.S. opioid kickback probe

Balancing Opioid Addiction Risk with Pain Management Needs

Larry Beresford  |  February 18, 2018

SAN DIEGO—During a session at the ACR/ARHP 2017 Annual Meeting Nov. 3–8, three representatives from the federal government described several of the government’s varied national strategies and agencies that are tackling pain. All of these strategies are affected by the current national epidemic of opioid overdoses and the need for safer analgesic prescribing. But the…

Filed under:AnalgesicsDrug UpdatesEthicsLegal UpdatesMeeting Reports Tagged with:ACR/ARHP Annual Meetingopioid epidemicPain Management

Opioid Makers Paid Millions to Advocacy Groups

Nate Raymond  |  February 14, 2018

(Reuters)—Five opioid manufacturers, including OxyContin maker Purdue Pharma LP, have paid more than $10 million to advocacy groups and doctors tied to them, many of whom amplified industry messages supporting the use of the painkillers, a U.S. Senate report said on Monday.1 The report, released by Sen. Claire McCaskill (D-Mo.), says groups who received the…

Filed under:AnalgesicsDrug Updates Tagged with:national opioid addiction epidemicOpioid abuseopioid crisisOpioid manufacturersU.S. Senate

Neurontin Prescriptions Surge Amid Opioid Crisis

Cindy Devone-Pacheco  |  January 4, 2018

(Reuters Health)—Prescriptions for nerve pain medicines like Neurontin and Lyrica have more than tripled in recent years, driven by increased use among chronically ill older adults and patients already taking opioids, a U.S. study suggests. The proportion of U.S. adults prescribed Neurontin and other drugs in the same family of medicines climbed from 1.2% in…

Filed under:Drug Updates Tagged with:gabapentinoidsLyricanational opioid addiction epidemicNeurontinNeurontin prescription surgeopioid crisis

U.S. Life Expectancy Fell in 2016 as Opioid Overdoses Surged—CDC

Reuters Staff  |  December 26, 2017

NEW YORK (Reuters)—Life expectancy in the United States dipped in 2016 as the number of deaths due to opioid drug overdoses surged and total drug overdose deaths rose 21% to 63,600, the U.S. Centers for Disease Control and Prevention said on Thursday. Life expectancy fell to 78.6 years, a decrease of 0.1 year from 2015,…

Filed under:Uncategorized Tagged with:opioid crisisopioid drug overdosesU.S. Centers for Disease Control and PreventionU.S. opioid addiction epidemicUnited States life expectancy 2016

New Jersey Sues OxyContin Maker, Links Marketing to Opioid Crisis

Jonathan Stempel  |  November 1, 2017

(Reuters)—New Jersey on Tuesday sued Purdue Pharma LP, accusing the OxyContin maker of contributing to the state’s opioid crisis through deceptive marketing to doctors and patients, including the elderly and the “opioid-naive.” Christopher Porrino, the New Jersey attorney general, faulted what he called a decade-long marketing campaign of “almost inconceivable callousness and irresponsibility, and said…

Filed under:Drug UpdatesLegal Updates Tagged with:deceptive marketingnational opioid addiction epidemicNew Jersey lawsuitopioid crisisOxyContin makerPurdue Pharma LP

Billionaire Insys Founder Charged in U.S. Opioid Bribe Case

Nate Raymond  |  October 27, 2017

BOSTON (Reuters)—The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic. John Kapoor, Insys’ majority shareholder who stepped down as chief executive in January, was charged…

Filed under:Legal Updates Tagged with:billionaire Insys founderCancerfentanyl-based cancer pain drugInsys Therapeutics IncJohn Kapoornational opioid addiction epidemicopioid crisisU.S. opioid bribe case

Trump Declares Opioids a U.S. Public Health Emergency

Yasmeen Abutaleb and Jeff Mason  |  October 27, 2017

WASHINGTON (Reuters)—U.S. President Donald Trump declared the opioid crisis a public health emergency on Thursday, stopping short of a national emergency declaration he promised months ago that would have freed up more federal money. Responding to a growing problem wreaking havoc in rural areas, Trump’s declaration will redirect federal resources and loosen regulations to combat…

Filed under:Drug Updates Tagged with:Fentanylnational opioid addiction epidemicopioid crisisprescription painkillersU.S. public health emergency

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 9
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences